Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Badger Meter Inc (BMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Badger Meter Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Badger Meter Inc trades at $135.56 (market cap $3.95B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and Badger Meter Inc pays a 1.17% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BMI | |
|---|---|---|
Market Cap | $5.06B | $3.95B |
Sector | Health | Technology |
52-Week High | $29.41 | $193.09 |
52-Week Low | $20.06 | $113.41 |
Enterprise Value | $4.18B | $3.86B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
Badger Meter (BMI) trades at $138.86, up 1.23% today, with a bullish technical signal from moving averages and a consensus analyst price target of $155.20. Recent earnings show a Q2 2026 beat but misses in prior quarters, while financials indicate solid profitability with a 14.27% net income margin. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by Business Wire and GlobeNewsWire in early August 2026, though insider buying by a VP in late July signals confidence.
The outlook is mixed: strong fundamentals and analyst upside support growth, but legal risks and earnings volatility pose challenges. Investors may find value if legal concerns resolve, but caution is warranted due to potential sentiment pressure from ongoing litigation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Badger Meter Inc
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →
